Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05118074 · ClinicalTrials.gov registry record
Nova Max Creatinine and eGFR Meter System
A clinical trial, sponsored by Nova Biomedical.
- Completed
- Registry status
- 360
- Enrollment target
NCT05118074: Completed study, sponsored by Nova Biomedical.
NCT05118074 is a clinical trial that has completed, run by Nova Biomedical. The registered enrollment target is 360 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05118074 has completed, sponsored by Nova Biomedical.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
Study Summary
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (the Siemens EXL creatinine determination). To assess the Ease of Use of the Nova Max Creatinine and eGFR Meter System in the hands of the intended CLIA-Waived Point-of-Care users.
Primary Outcome
Nova Max creatinine and eGFR meter system, a point of care testing instrument is as effective as a reference laboratory method for Creatinine blood results in mg/dL
Interventions
- DIAGNOSTIC_TEST Creatinine, eGFR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2024-04-15 |
What the finished NCT05118074 record still lists
NCT05118074 is an observational study that tracks outcomes without assigning an intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Creatinine, eGFR is the first listed.
NCT05118074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05118074 about?
NCT05118074 is a clinical study titled "Nova Max Creatinine and eGFR Meter System". To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (th...
What is the current status of trial NCT05118074?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2021-06-08. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05118074?
The interventions under investigation include: Creatinine, eGFR (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05118074?
This trial is sponsored by Nova Biomedical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI